BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Other Events

BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Other Events
Item 8.01Other Events.

Story continues below

As reported previously, BioSig Technologies, Inc. (“BioSig” or the “Company”) recently retained Sherpa Technology Group, an intellectual property strategy firm based in Silicon Valley, and Sterne Kessler Goldstein & Fox P.L.L.C., a patent firm based in Washington DC, to help develop and execute a strategy for the development of BioSig’s patent portfolio. As a result of that collaboration, on May 9, 2018 BioSig filed one “omnibus” hardware and software patent application with multiple claim sets, and a multiple feature-set graphical user interface (“GUI”) design patent, with detailed technical descriptions across multiple BioSig elements of novelty. BioSig plans to expand the patent filings into a robust patent family with multiple domestic and international patents to obtain broad utility claims that cover apparatus, methods and systems in EP and general signal processing areas, and display patents for its key GUI innovations. BioSig may choose to accelerate the patent prosecution process for key claim sets, e.g., by utilizing the United States Patent and Trademark Office acceleration programs (Track One) to shorten the time to grant domestically, and the Patent Cooperation Treaty and Patent Prosecution Highway to streamline and accelerate foreign filings as applicable.

Forward-lookingStatements

This report contains “forward-lookingstatements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.Forward-lookingstatements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by suchforward-lookingstatements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the Company’s inability to manufacture its product candidates on a commercial scale on its own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of the Company’s competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market the Company’s product candidates. More detailed information about the Company and the risk factors that may affect the realization offorward-lookingstatements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-lookingstatements as a result of new information, future events or otherwise.


About BioSig Technologies, Inc. (OTCMKTS:BSGM)

BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.

An ad to help with our costs